Show simple item record

dc.contributor.authorRolfo, C
dc.contributor.authorSwaisland, H
dc.contributor.authorLeunen, K
dc.contributor.authorRutten, A
dc.contributor.authorSoetekouw, P
dc.contributor.authorSlater, S
dc.contributor.authorVerheul, H
dc.contributor.authorFielding, A
dc.contributor.authorSo, K
dc.contributor.authorBannister, W
dc.contributor.authorDean, Emma J
dc.date.accessioned2015-08-12T14:24:22Zen
dc.date.available2015-08-12T14:24:22Zen
dc.date.issued2015-06en
dc.identifier.citationEffect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors. 2015, 32 (6):510-22 Adv Theren
dc.identifier.issn1865-8652en
dc.identifier.pmid26048134en
dc.identifier.doi10.1007/s12325-015-0214-4en
dc.identifier.urihttp://hdl.handle.net/10541/566201en
dc.description.abstractThe oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of ≤400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA-mutated ovarian and breast cancer.
dc.language.isoenen
dc.rightsArchived with thanks to Advances in therapyen
dc.titleEffect of food on the pharmacokinetics of Olaparib after oral dosing of the capsule formulation in patients with advanced solid tumors.en
dc.typeArticleen
dc.contributor.departmentUniv Antwerp Hosp, Dept Oncol, Early Clin Trials Unit, B-2650 Edegem, Belgiumen
dc.identifier.journalAdvances in Therapyen
html.description.abstractThe oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of ≤400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA-mutated ovarian and breast cancer.


This item appears in the following Collection(s)

Show simple item record